Stocktoria
XOMA Royalty Corp XOMA
XOMA Royalty Corp (XOMA) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It pays a dividend yielding 0.74% (safety: safe). FY2025 revenue was $52.1M at a 60.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.302 |
| Retained earnings / assets | -4.479 |
| EBIT / assets | 0.042 |
| Equity / liabilities | 0.497 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| XOMA | XOMA Royalty Corp | 5/9 | -11.82 | 23.3 | +83.1% |
| OCUL | OCULAR THERAPEUTIX, INC | 3/9 | 3.49 | — | -18.5% |
| QTTB | Q32 Bio Inc. | 3/9 | -2.11 | 7.5 | — |
| AGIO | AGIOS PHARMACEUTICALS, INC. | 2/9 | 12.52 | — | +48% |
| LXRX | LEXICON PHARMACEUTICALS, INC. | 3/9 | — | — | +60.2% |
| NKTR | NEKTAR THERAPEUTICS | 1/9 | — | — | -43.9% |
| GOSS | Gossamer Bio, Inc. | — | — | — | -57.7% |
About XOMA Royalty Corp
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
FAQ
Is XOMA financially healthy?
XOMA Royalty Corp's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does XOMA pay a dividend, and is it safe?
Yes. XOMA Royalty Corp pays a dividend yielding about 0.74% with a 17.3% payout ratio, rated “safe” for safety.
How profitable is XOMA?
In FY2025, XOMA Royalty Corp had a net margin of 60.8% and a return on equity of 37.8%.
What is XOMA's P/E ratio?
XOMA Royalty Corp's trailing price-to-earnings (P/E) ratio is about 23.3×, based on its latest annual earnings.
What is the analyst price target for XOMA?
The average Wall-Street price target for XOMA Royalty Corp is $39.00, from 1 analysts.
Is XOMA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on XOMA Royalty Corp: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone, a P/E of about 23.3×, a dividend yield of 0.74%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.